Back to bone: Optimising patient outcomes in metastatic bone disease

EAUN Industry Session by AMGEN

  • Location:
    Room 5
  • Chair:
     L. Drudge-Coates, London (GB)
  • Aims and objectives of this session

    • To consider and discuss the impact of bone metastases in urological cancer, with a focus on the changing treatment approaches in Metastatic Castration Resistant Prostate Cancer (mCRPC) and the subsequent practical considerations in decision making, in a clinical consultation
    • To provide an overview of symptoms and their causes in patients with bone metastases
    • To provide an overview of symptom assessment tools and maximising their use in the clinical setting to optimise quality of life

Introduction  L. Drudge-Coates, London (GB)
The shifting prostate cancer treatment paradigm: Implications of increased patient survival
 B. Tombal, Brussels (BE)
Optimising the patient clinical consultation: Symptom assessment tools
 B. Quinn, London (GB)